1. Tumor-derived cyclooxygenase-2 fuels hypothalamic inflammation.
- Author
-
Li X, Zhu X, Diba P, Shi X, Vrieling F, Jansen FAC, Balvers MGJ, de Bus I, Levasseur PR, Sattler A, Arneson-Wissink PC, Poland M, Witkamp RF, van Norren K, and Marks DL
- Subjects
- Animals, Mice, Receptors, Prostaglandin E, EP4 Subtype metabolism, NF-kappa B metabolism, Mice, Inbred C57BL, Neoplasms metabolism, Male, Mice, Knockout, Cell Line, Tumor, Hypothalamus metabolism, Cyclooxygenase 2 metabolism, Inflammation metabolism, Dinoprostone metabolism, Lipopolysaccharides pharmacology
- Abstract
Hypothalamic inflammation often coincides with cancer and cachexia-anorexia. Prior work established the significance of tumor-derived inflammatory factors in triggering hypothalamic inflammation, yet the precise mechanisms remained elusive. Here, we demonstrate that prostaglandin E2 (PGE2), produced in the tumor via cyclooxygenase-2 (COX-2), plays a pivotal role in this context. PGE2 itself directly exerts pro-inflammatory effects on the hypothalamus through the EP4 receptor, while also augmenting hypothalamic inflammation via NF-κB pathways in the presence of host gut-derived pathogen-associated molecular patterns (PAMPs). In tumor-bearing mice, we confirm this synergistic interaction between tumor-derived COX-2/PGE2 and host-derived lipopolysaccharide (LPS) in amplifying hypothalamic inflammation. Supporting this mechanism we find that the tumor-specific knockout of COX-2 attenuates hypothalamic inflammation and improves survival in mice. Together, these findings highlight the mechanisms of tumor-associated COX-2 in fuelling hypothalamic inflammation. They also emphasize the potential of tumor-specific COX-2 inhibition and targeting gut permeability as a novel therapeutic strategy for improving clinical outcomes in cancer patients., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: D.L.M. is a consultant, chief medical officer, stockholder, and has received grant funding from Endevica Bio, Inc. D.L.M. is a consultant for Alkermes, Inc. and Pfizer, Inc. X.Z. is a stockholder in Endevica Bio, Inc. The other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF